Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
GoodRx Holdings
GDRX
GoodRx Holdings
Digital Transformation And Aging Trends Will Expand Affordable Prescription Access
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 14 Analysts
Published
25 Aug 25
Updated
25 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$7.00
38.1% undervalued
intrinsic discount
25 Aug
US$4.33
1Y
-49.6%
7D
-7.3%
Loading
1Y
-49.6%
7D
-7.3%
Author's Valuation
US$7.0
38.1% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$7.0
38.1% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-282m
983m
2018
2020
2022
2024
2025
2026
2028
Revenue US$983.5m
Earnings US$204.6m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
5.78%
Healthtech revenue growth rate
4.32%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.73%
Calculation
US$204.60m
Earnings '28
x
12.25x
PE Ratio '28
=
US$2.51b
Market Cap '28
US$2.51b
Market Cap '28
/
279.47m
No. shares '28
=
US$8.97
Share Price '28
US$8.97
Share Price '28
Discounted to 2025 @ 8.68% p.a.
=
US$6.99
Fair Value '25